<DOC>
	<DOC>NCT02835274</DOC>
	<brief_summary>The primary objective is to characterize the programming effects of Boston Scientific Vercise™ PC System using the DBS Directional Lead for bilateral STN DBS for the treatment of Parkinson's disease in acute and chronic settings.</brief_summary>
	<brief_title>Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Key Diagnosis of bilateral idiopathic PD with the presence of rigidity and at least one (1) of the following: resting tremor or bradykinesia. UPDRS III score of &gt;25 in the meds OFF condition Medication must improve PD symptoms by ≥30%, as measured by UPDRS subset III score Key Any significant psychiatric problems, including unrelated clinically significant depression as determined by the investigator Any current drug or alcohol abuse as determined by the investigator Any history of recurrent or unprovoked seizures Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival &lt;12 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>parkinson disease</keyword>
	<keyword>deep brain stimulation</keyword>
	<keyword>directional stimulation</keyword>
</DOC>